Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals.

ABSTRACT: Monotherapy of HIV-1 infection with single antiretroviral agents is ineffective because error-prone HIV-1 replication leads to the production of drug-resistant viral variants^1,2. Combinations of drugs can establish long-term control, however, antiretroviral therapy (ART) requires daily dosing, can cause side effects and does not eradicate the infection^3,4. Although anti-HIV-1 antibodies constitute a potential alternative to ART^5,6, treatment of viremic individuals with a single antibody also results in emergence of resistant viral variants^7-9. Moreover, combinations of first-generation anti-HIV-1 broadly neutralizing antibodies (bNAbs) had little measurable effect on the infection^10-12. Here we report on a phase 1b clinical trial ( NCT

SUBMITTER: Bar-On Y 

PROVIDER: S-EPMC6221973 | biostudies-literature | 2018 Nov

REPOSITORIES: biostudies-literature